Key Details
Price
$91.08Annual Revenue
$2.24 BAnnual EPS
-$0.30PE Ratio
36.14Annual ROE
-0.88%Beta
0.10Events Calendar
Next earnings date:
Feb 21, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Feb 16, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Dec 05, 2006Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Amedisys' expected merger with UnitedHealth Group's Optum brings optimism to investors. Yet, a dull macroeconomic condition adds to the worry.
On Friday afternoon, key U.S. stock indexes fell as technology shares declined.
UnitedHealth Group (UNH) and Amedisys (AMED) agreed to extend the deadline to complete their $3.3 billion merger, after the U.S. Department of Justice moved to block it.
Amedisys Inc AMED shares are trading higher on Friday after the company announced it extended its merger deadline with UnitedHealth Group Incorporated UNH.
Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Amedisys (AMED) and Chemed (CHE). But which of these two companies is the best option for those looking for undervalued stocks?
Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Amedisys (AMED) and Chemed (CHE). But which of these two stocks is more attractive to value investors?
Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BATON ROUGE, La., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care in the home, has 92 home health and hospice care centers recognized by Strategic Healthcare Programs (SHP) for achieving the highest overall HHCAHPS patient satisfaction or CAHPS Hospice caregiver satisfaction scores of all eligible SHP clients in 2023. This includes 14 care centers awarded Premier Performer, ranking in the top 5%, and 78 care centers awarded Superior Performer, ranking in the top 20%. Thirteen care centers achieved an award in each of the last 5 years of the SHPBest program.
FAQ
- What is the primary business of Amedisys?
- What is the ticker symbol for Amedisys?
- Does Amedisys pay dividends?
- What sector is Amedisys in?
- What industry is Amedisys in?
- What country is Amedisys based in?
- When did Amedisys go public?
- Is Amedisys in the S&P 500?
- Is Amedisys in the NASDAQ 100?
- Is Amedisys in the Dow Jones?
- When was Amedisys's last earnings report?
- When does Amedisys report earnings?
- Should I buy Amedisys stock now?